Amur Minerals Corporation Receipt of Funds (9466S)
15 March 2023 - 12:00AM
UK Regulatory
TIDMAMC
RNS Number : 9466S
Amur Minerals Corporation
14 March 2023
14 March 2023
Amur Minerals Corporation
("Amur" or the "Company")
Receipt of Funds
Amur Minerals Corporation ("Amur" or the "Company"), is pleased
to confirm it is in receipt of the agreed consideration, an amount
of US$35 million, for the sale of the Company's 100% interest in
its nickel - copper sulphide asset, Kun-Manie, located in the
Russian Federation.
The Company has previously announced that it will pay a special
dividend of 1.8 pence per share to shareholders within 90 days of
the receipt of funds. Further announcements in respect of the
dividend dates will be made in due course.
Following the disposal of Kun-Manie on 06 March 2023, Amur
Minerals became an AIM Rule 15 cash shell and accordingly, is
required to make an acquisition or acquisitions which constitute(s)
a reverse takeover under AIM Rule 14 on or before the date falling
six months from the completion of the disposal, or be re-admitted
to trading on AIM as an investing company under AIM Rule 8. Failing
that, the Company's ordinary shares would be suspended from trading
on AIM pursuant to AIM Rule 40. If the Company's shares remain
suspended for six months, admission of the Company's shares will be
cancelled.
For further information, and Company updates see the Company
website at www.amurminerals.com twitter page @ amur_minerals.
Market Abuse Regulation (MAR) Disclosure
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with
the Company's obligations under Article 17 of MAR.
Enquiries:
Company Nomad and Broker Public Relations
Amur Minerals Corp. S.P. Angel Corporate BlytheRay
Finance LLP
Robin Young CEO Richard Morrison Megan Ray
Adam Cowl Tim Blythe
+44 (0) 20 3470
+1 (925) 408-4621 0470 +44 (0) 20 7138 3204
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFSFVSISLIV
(END) Dow Jones Newswires
March 14, 2023 09:00 ET (13:00 GMT)
Crism Therapeutics (AQSE:AMC.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Crism Therapeutics (AQSE:AMC.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024